Approval · Notice of Compliance 2220 · 2001
NEXIUM: Notice of Compliance 2220
Issued August 17, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2220
- Date
- August 17, 2001
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- H+,K+-ATPase Inhibitor
Products in this notice
Medicinal ingredients
- ESOMEPRAZOLE MAGNESIUM TRIHYDRATE 20 MG per TAB
- ESOMEPRAZOLE MAGNESIUM TRIHYDRATE 40 MG per TAB